Using targeted radiotherapy to improve outcomes in men with metastatic prostate cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This phase II clinical trial investigates the effectiveness of Stereotactic Ablative Body Radiotherapy (SABR) in men with metastatic prostate cancer who have achieved a maximal systemic response to standard therapy. Eighty participants will be randomly selected to receive SABR based on disease detected by PSMA-PET imaging. The primary goal is to evaluate the rate of freedom from progression (FFP) at one year, with patients categorized by hormone sensitivity prior to randomization. The study aims to provide insights into the potential benefits of consolidative radiotherapy in this patient population.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Enrolled in PERa (CHUM CER 17.032) and randomly selected for ANCHOR-Prostate.
* Diagnosis of hormone-sensitive metastatic prostate cancer having responded to systemic therapy.
* PSA non-progressing
* ECOG 0-2
* Metastatic disease suitable for MDRT.
* Primary tumor must have received definitive local treatment (surgery or radiotherapy) with no evidence of local recurrence, or be planned for treatment at the time of MDRT.

Exclusion Criteria:

* Planned intermittent systemic therapy.
* Planned radio-ligand therapy.

Where it's running

• Crchum
  Montreal, Quebec, Canada Recruiting

Study contacts

• Study coordinator: Mom Phat
• Email: mom.phat.chum@ssss.gouv.qc.ca
• Phone: 514-890-8254

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Epidemiology, diagnosis, and treatment patterns of prostate cancer in Algeria

  This project collects medical and treatment information to see how prostate cancer is diagnosed and managed in Algerian men with confirmed disease.

  Recruiting at 21 sites Société Algérienne de Formation et Recherche en Oncologie · Adrar, Algeria and 23 other locations · NCT07484971

• OM-RCA-01 (anti-FGFR1 antibody) for metastatic tumors that express FGFR1

  This trial will try OM-RCA-01, an IV antibody given every two weeks, in adults with metastatic cancers whose tumors test positive for FGFR1 and who have progressed after standard treatments.

  Recruiting at 4 sites Phase 1/2 Kidney Cancer Research Bureau · Kazan' and 4 other locations · NCT07292168

• First-in-human testing of repeated autologous TIL immunotherapy for metastatic colorectal and prostate cancer

  This trial tests whether repeated infusions of a patient’s own tumor-infiltrating lymphocytes (TILs) can persist longer in the blood and help people with metastatic colorectal or prostate cancer.

  Recruiting Phase 1/2 CuraCell TX AB · Frankfurt · NCT07255664

• PSMA PET to predict treatment response in advanced prostate cancer

  This will test whether PSMA PET scans can help predict how advanced prostate cancer will respond to systemic treatments such as hormone therapy, chemotherapy, or PSMA-targeted radioligand therapy.

  Recruiting at 4 sites IRCCS Azienda Ospedaliero-Universitaria di Bologna · Bologna, Italy and 3 other locations · NCT07089550

• Treatment for advanced prostate cancer using Pluvicto

  This study is testing if a new treatment called Pluvicto can help men with advanced prostate cancer that has spread to their bones feel better and improve their quality of life.

  Recruiting Phase 2 Excel Diagnostics and Nuclear Oncology Center · Houston, Texas · NCT06972628

• 7-day water-only fasting for metastatic prostate cancer

  This study will test whether a 7-day water-only fast (with a ketogenic very low-calorie option) is safe and doable for people with metastatic prostate cancer.

  Recruiting Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · Baltimore, Maryland · NCT06826924

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.